Belite Bio BLTE 深 沪
已收盘 08-14 16:00:00 美东时间
162.80
-3.480
-2.09%
华盛通- 最 高167.00
- 今 开166.51
- 成交量 22.88万股
- 最 低 159.00
- 昨 收 166.28
- 总市值 65.26亿
- 52周最高 200.00
- 市盈率 静 --
- 换手率 0.57%
- 52周最低 62.18
- 委 比 12.43%
- 总股本 4008.51万
- 历史最高 200.00
- 量 比 1.01
- 振 幅 4.81%
- 历史最低 8.80
- 每 手 1
- 风险率 37.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Belite Bio reports Q2 results
Belite Bio press release (BLTE): Q2 non-GAAP net loss of $21.6M, compared to a non-GAAP net loss of $8.7M for the same period in 2025. Cash and Cash Equivalents: As of June 30, 2026, the company had $...
08-13 22:44
Belite Bio Q2 Adj. EPS $(0.54) Beats $(0.79) Estimate
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.79) by 31.65 percent. This is a 8 percent decrease over losses of $(0.50) per share from the same period last year.
08-13 15:08
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
CoreWeave To Rally Around 95%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. raised the price target for Belite Bio Inc (NASDAQ:BLTE) from $200 to $214. HC Wainwright ...
08-12 19:53
HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $214
HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $200 to $214.
08-12 19:36
Belite Bio wins FDA priority review for lead candidate
The U.S. Food and Drug Administration has accepted the marketing application for Belite Bio’s (BLTE) lead asset tinlarebant, granting the priority review for the eye disease therapy with a target acti...
08-12 18:58
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
Belite Bio announced that the FDA has accepted and granted Priority Review for the NDA of tinlarebant for Stargardt Disease Type 1 (STGD1), with a PDUFA date of February 12, 2027. The Phase 3 DRAGON trial showed a 35.7% reduction in atrophic retinal lesion growth rate compared to placebo. Tinlarebant, if approved, would be the first FDA-approved treatment for STGD1, a rare genetic eye disease causing progressive vision loss. The company highlight...
08-11 20:01
Why Is Belite Bio Stock Gaining Monday?
Belite Bio Inc (NASDAQ:BLTE) on Monday unveiled additional secondary endpoint statistics from its ongoing Phase 3 DRAGON trial. Following the announcement, the stock gained over 3%. The latest clinical data specifically highlights the performance of its drug candidate, tinlarebant, in treating Starg...
07-21 01:35
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
Belite Bio, a clinical-stage drug development company focused on treating degenerative retinal diseases, announced its participation in the H.C. Wainwright Ophthalmology Virtual Conference on July 22, 2026. The company will discuss its lead candidate, tinlarebant, an oral therapy targeting bisretinoid toxins in the eye. Belite Bio has completed Phase 3 trials for STGD1 and is conducting Phase 2/3 and Phase 3 trials for STGD1 and GA, respectively....
07-15 12:00
